Prospective natural history study of extracellular vesicle metabolimic biomarkers of myotonic dystrophy

Active Grant Awarded

Award ID
R01FD008236
Recipient
Awarding agency
Obligated
$400,000

Award facts

Assistance listing
93.103 Food and Drug Administration Research
Completion date 4% complete
Funding agency
Office of Medical Products and Tobacco Food and Drug Administration, Department of Health and Human Services
Place of performance
Boston, MA 02114, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services Food and Drug Administration awarded Grant R01FD008236, with $400,000 obligated, to The General Hospital Corporation, doing business as Massachusetts General Hospital, on Sep 23, 2026, under Assistance Listing 93.103, Food and Drug Administration Research. The award funds a prospective natural history study of extracellular vesicle (EV) metabolomic biomarkers of myotonic dystrophy type 1 (DM1). The study tests whether urinary EVs carry a representative metabolome that is altered in DM1 and quantifiable in urine, as a minimally invasive alternative to the serial muscle biopsies currently required to monitor antisense oligonucleotide treatment effects.

Aim 1 identifies and characterizes the EV metabolomic profile in DM1 and compares it to the transcriptomic profile. The work uses liquid chromatography and mass spectrometry (LC/MS) to quantify metabolites and droplet digital PCR (ddPCR) to quantify transcripts.

The period of performance runs from the award date to an ultimate completion date of Aug 31, 2030. Place of performance is Boston, MA 02114. The funding agency record lists the Office of Medical Products and Tobacco as an alternate name.

Description

Abstract
Myotonic dystrophy type 1 (dystrophia myotonica; DM1) is an inherited disorder that causes progressive muscle weakness and wasting. No effective treatments are available to slow or reverse symptoms. Candidate therapeutic antisense oligonucleotides (ASOS) are being tested in ongoing clinical trials. Monitoring drug treatment effects in these studies currently requires that patients undergo serial muscle biopsies, a procedure that is invasive, painful, and impractical for long-term monitoring. As a result, interest has been increasing to identify minimally invasive biomarkers that are sensitive to molecular disease status, identify drug target engagement, enable frequent sampling, are easy to apply across clinical sites, and improve patient quality of life. Extracellular vesicles (EVS), which are membrane-encased particles released and taken up by cells as a form of extracellular communication, are emerging as important tools for the study of tissue pathophysiology. EVS contain mrna, non-coding rnas, micrornas, collectively termed extracellular rnas (EXRNAS) that can serve as biomarkers of cancers and other disease states. EVS released into the urine or blood carry exrna, proteins, and metabolites that reflect the molecular physiology and pathology of origin tissues. Recent work has suggested that urinary EVS contain metabolites and exrna cargo that may have the capacity to serve as robust monitoring biomarkers of DM1. This prospective natural history study will test the hypothesis that EVS contain a representative metabolome that is altered in DM1 and is quantifiable in urine. Aim 1 will focus on identifying and characterizing the EV metabolomic profile in DM1 and compare to the transcriptomic profile. Liquid chromatography and mass spectrometry (LC/MS) will be used to quantify metabolites. Droplet digital PCR (DDPCR) will be used to quantify the transcriptome. To increase sensitivity for the identification of early EV indicators of disease status, we will use dimensionality reduction methods that combine individual biomarkers to form a single interpretive readout known as a composite biomarker for each individual. Aim 2 will establish the feasibility and reliability of EV rnas or metabolites as useful biomarkers of DM1 by longitudinal monitoring in participants over a two-year period (N = 5 visits per subject). Aim 3 will identify the relationship between EV profiles and disease severity using clinical outcome assessments (COAS), including quantitative muscle strength and motor function, muscle impairment rating scale (MIRS), patient reported outcomes, and kidney function by cystatin C-based estimated glomerular filtration rate (EGFR). The proposed context of use is monitoring biomarkers for serial assessment of disease status or burden in patients with DM1. Our approach will expand our understanding of DM1 pathophysiology and accelerate the development of new treatments.

Quick answers

Who received award R01FD008236?

R01FD008236 was awarded to The General Hospital Corporation by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 23, 2026.

How much is award R01FD008236 worth?

$400,000 has been obligated on R01FD008236.

Which agency awarded R01FD008236?

FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD008236, with funding from Office of Medical Products and Tobacco (Food and Drug Administration).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award